Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
Lumos Pharma, Inc. (NASDAQ:LUMO) announced its participation at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021. The company will present live from 10:45 AM to 11:25 AM ET and will also conduct virtual one-on-one meetings with investors. The presentation can be accessed via the company’s website and will be available for replay for 90 days. Lumos Pharma is focused on therapeutics for rare diseases, with its lead candidate, LUM-201, currently in a Phase 2b trial for Pediatric Growth Hormone Deficiency (PGHD).
- None.
- None.
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day.
| Event: | Oppenheimer Rare & Orphan Disease Summit | ||
| Date: | May 21, 2021 | ||
| Time: | Live Presentation 10:45 AM – 11:25 AM (ET) |
The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com). The link can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay will be available for 90 days. Please contact your Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the Summit or thereafter.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
What is the date of the Oppenheimer Rare & Orphan Disease Summit for Lumos Pharma?
What time will Lumos Pharma's presentation occur during the summit?
How can I access Lumos Pharma's presentation at the summit?
What is Lumos Pharma's lead candidate in development?
Is LUM-201 designed for oral administration?
